Compare IDEXX Laboratories, Inc. (IDXX) vs Meta Platforms Inc (META) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Meta Platforms Inc — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while Meta Platforms Inc trades at $718.67 (market cap $1.84T). The key difference: Meta Platforms Inc is far larger — about 45.5× IDEXX Laboratories, Inc.'s market cap, and Meta Platforms Inc pays a 0.29% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Meta Platforms Inc for 127 Days on average.
| IDXX | META | |
|---|---|---|
Market Cap | $40.43B | $1.84T |
Volume | 692,164 | 15,887,049 |
Sector | Health | Media |
52-Week High | $766.68 | $777.59 |
52-Week Low | $504.70 | $525.72 |
Typical Hold Time | 46 Days | 127 Days |
Enterprise Value | $41.32B | $1.86T |
Dividend Yield | — | 0.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $513.14, up 1.28% with strong fundamentals including 25.03% net income margin and 74.21% ROE. The stock shows bearish technical signals but maintains consistent earnings beats and analyst consensus of $665 price target. Recent acquisition of CoVetAI expands AI capabilities in veterinary workflow intelligence, supporting long-term growth framework.
Outlook remains positive with revenue growth accelerating to $4.3B in 2025 and projected $4.6B in 2026. Key risks include foreign exchange headwinds and weaker U.S. veterinary visits. The 56.5% buy rating from analysts suggests continued confidence in the company's diagnostic innovation pipeline and recurring revenue economics.
Meta Platforms (META) trades at $720.89, down 0.06% on the day, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust fundamentals with $201B revenue in 2025 and 29.84% net income margin, though Q2 2026 earnings missed expectations. Recent AI developments including the Muse Spark launch and a $21B CoreWeave deal highlight strategic positioning in artificial intelligence infrastructure.
Wall Street maintains strong bullish sentiment with 80% buy ratings and $781 consensus price target, representing 8% upside. Key risks include ongoing youth addiction litigation in Massachusetts and elevated capital expenditures for AI infrastructure. The stock presents growth potential through AI monetization but faces regulatory and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Meta Platforms Inc
Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →
